Order Targets Sales But Ignores Manufacturing Flaws
The recent government order to curb cough syrup sales is an incomplete prescription that does not tackle the real problem at the manufacturing stage. According to a report by DHNS published on 21 June 2026, the syrups are contaminated with dangerous chemicals, but the order focuses only on distribution and sales.
Contamination Root Cause Remains Unaddressed
The order fails to mandate stricter quality checks or inspections at manufacturing units. Experts point out that without addressing contamination during production, the risk of harmful products reaching consumers persists. The DHNS report highlights that dangerous chemicals have been found in multiple batches, yet no corrective action has been taken at the source.
Impact on Public Health
This oversight leaves public health vulnerable. Contaminated cough syrups have been linked to adverse effects, including kidney damage and deaths in some cases. The incomplete prescription raises concerns about the government's commitment to ensuring drug safety.
Call for Comprehensive Action
Health advocates urge authorities to expand the order to include mandatory testing of raw materials and finished products at manufacturing sites. Until then, the curbs remain a partial measure that does not guarantee safe medicines for consumers.
